Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497642 | 0.87 | LRRK2 (0.57) | LRRK2P2RX1CYP1A2P2RX4P2RX7 | |
| SCHEMBL16707259 | 0.87 | LRRK2 (0.55) | LRRK2P2RX1CYP1A2P2RX4P2RX7 | |
| SCHEMBL6102385 | 0.85 | LRRK2 (0.52) | LRRK2CYP1A2NR1H4PPARGPPARA | |
| SCHEMBL20280065 | 0.83 | LRRK2 (0.53) | LRRK2P2RX1CYP1A2P2RX4P2RX7 | |
| SCHEMBL6103242 | 0.82 | LRRK2 (0.57) | LRRK2P2RX1CYP1A2 | |
| SCHEMBL17859072 | 0.82 | LRRK2 (0.52) | LRRK2NR1H4PPARGPPARAPPARD | |
| SCHEMBL17858986 | 0.82 | LRRK2 (0.60) | LRRK2P2RX1P2RX4P2RX7NR1H4 | |
| SCHEMBL3498496 | 0.81 | P2RX1 (0.48) | P2RX1P2RX4P2RX7 | |
| SCHEMBL131166 | 0.78 | LRRK2 (0.63) | LRRK2P2RX1SRPK3 | |
| SCHEMBL130386 | 0.78 | LRRK2 (0.62) | LRRK2P2RX1P2RX4P2RX7SRPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | LRRK2 4237/4885P2RX1 2507/4885TRPA1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.